Alternative therapies in health and medicine · 2024
Impact of Combined Nifedipine and Aspirin Therapy on Hemodynamics in Patients with Early Eclampsia.
СтатьяРандомизированное исследованиеНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Fan Jinyu, Yang Yujiao, Wang Xiumei
Аннотация
BACKGROUND: Preeclampsia poses substantial risks during pregnancy. Exploring innovative treatment approaches like the combination of Nifedipine and aspirin is crucial for improving maternal and fetal outcomes.
OBJECTIVE: This study aims to assess the efficacy of nifedipine and aspirin tablets in treating preeclampsia and their impact on blood rheology and coagulation.
METHODS: We selected 96 pregnant patients with preeclampsia treated at our hospital between January 2020 and January 2022. The patients were randomly assigned to either the research group (n=48) or the control group (n=48). Nifedipine was administered to the control group, while the research group received a combination of Nifedipine and aspirin. We compared the overall treatment effectiveness and the incidence of unfavorable pregnancy outcomes between the two groups.
RESULTS: The research group exhibited a significantly higher overall treatment effectiveness rate (93.75%) compared to the control group (P < .05). After treatment, levels of fibrinogen (FIB), whole high-cut blood viscosity (HBV), whole low-cut blood viscosity (LBV), plasma viscosity (PV), and erythrocyte rigidity index (HGX) were significantly lower in the study group than in the control group (P < .05). Additionally, plasminogen time (PT) and activated partial thromboplastin time (APTT) were higher in the research group compared to the control group (P < .05). The research group also experienced a lower frequency of negative pregnancy outcomes (4.17%) in contrast to the control group (18.75%) (P < .05).
CONCLUSIONS: The nifedipine and aspirin combination effectively treats pregnancy hypertension, enhancing both coagulation and hemorheology for improved maternal and fetal health outcomes.
OBJECTIVE: This study aims to assess the efficacy of nifedipine and aspirin tablets in treating preeclampsia and their impact on blood rheology and coagulation.
METHODS: We selected 96 pregnant patients with preeclampsia treated at our hospital between January 2020 and January 2022. The patients were randomly assigned to either the research group (n=48) or the control group (n=48). Nifedipine was administered to the control group, while the research group received a combination of Nifedipine and aspirin. We compared the overall treatment effectiveness and the incidence of unfavorable pregnancy outcomes between the two groups.
RESULTS: The research group exhibited a significantly higher overall treatment effectiveness rate (93.75%) compared to the control group (P < .05). After treatment, levels of fibrinogen (FIB), whole high-cut blood viscosity (HBV), whole low-cut blood viscosity (LBV), plasma viscosity (PV), and erythrocyte rigidity index (HGX) were significantly lower in the study group than in the control group (P < .05). Additionally, plasminogen time (PT) and activated partial thromboplastin time (APTT) were higher in the research group compared to the control group (P < .05). The research group also experienced a lower frequency of negative pregnancy outcomes (4.17%) in contrast to the control group (18.75%) (P < .05).
CONCLUSIONS: The nifedipine and aspirin combination effectively treats pregnancy hypertension, enhancing both coagulation and hemorheology for improved maternal and fetal health outcomes.